KiNGTyreZe
Banned
- Reaction score
- 7
Anybody heard of that before?
Seems like a German pharma company worked with Setipiprant before but canceled their work.
Google Translate:
Source: http://www.handelszeitung.ch/news/actelion-setipiprant-mit-testmisserfolg-miglustat-japan-zugelassen
- - - Updated - - -
So they put their focus on more efficient follow-on compunt like a CRTH2 antagonist.
As we know PGD2 binds CRTH2 (DHT -> PGD2 -> CRTH2), and inhibitng CRTH2 showed to halt hair loss according to user reports.
Kane is offering TM30089 currently, which is a potent CRTH2 antagonist.
And it's cheaper than Setipiprant.
Seems like a German pharma company worked with Setipiprant before but canceled their work.
Google Translate:
Actelion: Setipiprant with Test Failure
Zurich (AWP) - The pharmaceutical company Actelion has suffered with the product candidates setipiprant in asthma and seasonal allergic rhinitis (hay fever) a failure. In two recently concluded studies with the novel, orally active CRTH2 antagonists setipiprant in Phase IIb in asthma and in a Phase III profiling study that observed in previous studies effectiveness could not be confirmed, the company shares on Monday. The clinical development of this well-tolerated in these indications substance will therefore set.
By contrast, Actelion announced the approval of miglustat for the treatment of Niemann-Pick C disease in Japan. The approval is based on study data from the EU and additional, specially raised for Japan data issued by the Japanese Ministry of Health, it said.
The development activities in the field of anti-inflammatory substances would realign and in future concentrate on an effective follow-up of a substance CRTH2 antagonists, it said. This would be in Phase I clinical development. From the focus on more efficient follow-on compound, the company new insights into the potential anti-inflammatory properties of the CRTH2 mechanism in allergic diseases promise.
Source: http://www.handelszeitung.ch/news/actelion-setipiprant-mit-testmisserfolg-miglustat-japan-zugelassen
- - - Updated - - -
So they put their focus on more efficient follow-on compunt like a CRTH2 antagonist.
As we know PGD2 binds CRTH2 (DHT -> PGD2 -> CRTH2), and inhibitng CRTH2 showed to halt hair loss according to user reports.
Kane is offering TM30089 currently, which is a potent CRTH2 antagonist.
And it's cheaper than Setipiprant.